Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Sophia Genetics SA (SOPH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: SOPH (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7
1 Year Target Price $7
| 4 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 12.25% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 225.04M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Price to earnings Ratio - | 1Y Target Price 7 | ||
Volume (30-day avg) 6 | Beta 1 | 52 Weeks Range 2.58 - 4.92 | Updated Date 08/29/2025 |
52 Weeks Range 2.58 - 4.92 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.1 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-04 | When Before Market | Estimate -0.22 | Actual -0.2457 |
Profitability
Profit Margin -105.32% | Operating Margin (TTM) -100.92% |
Management Effectiveness
Return on Assets (TTM) -23.46% | Return on Equity (TTM) -74.09% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 192679343 | Price to Sales(TTM) 3.23 |
Enterprise Value 192679343 | Price to Sales(TTM) 3.23 | ||
Enterprise Value to Revenue 2.76 | Enterprise Value to EBITDA -0.3 | Shares Outstanding 67579600 | Shares Floating 50710350 |
Shares Outstanding 67579600 | Shares Floating 50710350 | ||
Percent Insiders 6.46 | Percent Institutions 48.21 |
Upturn AI SWOT
Sophia Genetics SA
Company Overview
History and Background
Sophia Genetics SA, founded in 2011, is a Swiss-based bioinformatics company. It evolved from research at the University of Lausanne and the Swiss Federal Institute of Technology (EPFL). It focuses on data-driven medicine to improve diagnostics and treatment for patients.
Core Business Areas
- Data Analytics Platform: Development and provision of the SOPHiA DDM platform, which analyzes genomic and multimodal data to assist healthcare professionals in diagnostics and treatment decisions. The platform leverages AI and machine learning to improve accuracy and efficiency.
- Clinical Genomics Services: Offering clinical genomics services to hospitals, laboratories, and biopharmaceutical companies. These services include comprehensive genomic profiling, liquid biopsy analysis, and genetic testing for various diseases.
- Drug Discovery and Development Support: Providing data analytics and bioinformatics tools to support drug discovery and development processes. This includes target identification, biomarker discovery, and clinical trial optimization.
Leadership and Structure
The company has a structured leadership team including a CEO, CFO, and other key executives responsible for different functional areas. The board of directors oversees the strategic direction of the company.
Top Products and Market Share
Key Offerings
- SOPHiA DDM Platform: A cloud-based platform that analyzes complex genomic data to aid clinicians in making informed decisions. Competitors include companies like Illumina (ILMN) with its NextSeq platform and Roche (RHHBY) with its Foundation Medicine services. Market share data is difficult to pinpoint exactly, but Sophia Genetics aims to become a leader in this fast-growing segment of genomic data analytics. Reported revenue from this product would be included in overall company revenue figures.
- Oncology Solutions: Genomic profiling solutions focused on cancer diagnostics and treatment. These solutions identify actionable mutations and biomarkers. Competitors include Exact Sciences (EXAS) with its Oncotype DX test and Guardant Health (GH) with its Guardant360 liquid biopsy test. Market share and user data are not publicly available but are central to revenue.
Market Dynamics
Industry Overview
The market for genomic data analytics is rapidly growing, driven by advancements in sequencing technologies, increasing demand for personalized medicine, and growing adoption of liquid biopsies. It's a highly competitive landscape.
Positioning
Sophia Genetics SA is positioned as a leading provider of data analytics solutions for genomic and multimodal data, offering a comprehensive platform for clinical genomics and drug discovery. Its competitive advantage lies in its proprietary AI algorithms and extensive database of genomic information.
Total Addressable Market (TAM)
The total addressable market (TAM) for genomic data analytics is estimated to be in the billions of dollars and growing rapidly. Sophia Genetics SA is positioned to capture a significant portion of this market.
Upturn SWOT Analysis
Strengths
- Proprietary AI-driven data analytics platform
- Extensive genomic database
- Strong relationships with hospitals and research institutions
- Focus on innovation and development of new solutions
Weaknesses
- Relatively small market share compared to larger competitors
- High dependency on regulatory approvals
- Intense competition in the genomic data analytics market
- Historically unprofitable; reliant on funding
Opportunities
- Expanding into new geographic markets
- Developing new applications for its data analytics platform
- Forming strategic partnerships with biopharmaceutical companies
- Increasing adoption of personalized medicine
Threats
- Increased competition from larger, more established players
- Regulatory changes impacting the use of genomic data
- Data security and privacy concerns
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- ILMN
- ROCHE.SW
- EXAS
- GH
Competitive Landscape
Sophia Genetics SA faces intense competition from larger, more established players. Its advantages include its proprietary AI-driven data analytics platform and focus on innovation. Disadvantages include its smaller market share and financial losses.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by increased adoption of its SOPHiA DDM platform and expansion into new markets. However, it is tempered by current financial performance.
Future Projections: Future growth is projected to be driven by continued adoption of its platform, expansion into new applications, and strategic partnerships. Analyst estimates vary.
Recent Initiatives: Recent initiatives would include product launches, strategic partnerships, and expansion into new geographic markets.
Summary
Sophia Genetics SA is a promising bioinformatics company with a leading data analytics platform. While it faces stiff competition and profitability challenges, its AI-driven technology positions it well for future growth in the rapidly expanding market of genomic data analytics. Careful monitoring of financial performance and market competition is crucial. Overall, the company is in a somewhat weak position, but with strong potential for growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Analyst reports
- Industry publications
- SEC filings
- Third-party market research reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. The analysis is based on publicly available data and is subject to change. Market share data is approximate and based on available estimates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sophia Genetics SA
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-07-23 | Co-Founder, CEO & Director Dr. Jurgi Camblong M.B.A., Ph.D. | ||
Sector Healthcare | Industry Health Information Services | Full time employees 423 | Website https://www.sophiagenetics.com |
Full time employees 423 | Website https://www.sophiagenetics.com | ||
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is based in Rolle, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.